Recent EWTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 12:51:21 PM
- Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline • PR Newswire (US) • 06/01/2026 12:30:00 PM
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 • PR Newswire (US) • 05/12/2026 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 09:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:20:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:09:48 PM
- Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications • PR Newswire (US) • 05/07/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:29:58 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:49:16 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:10:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:07:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:06:20 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 04/01/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:41:21 PM
- Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 • PR Newswire (US) • 03/04/2026 01:00:00 PM
- Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference • PR Newswire (US) • 03/03/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 03/02/2026 02:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 01:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:00:52 PM
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs • PR Newswire (US) • 02/26/2026 01:00:00 PM
- Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 • PR Newswire (US) • 02/05/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 02/02/2026 01:00:00 PM
